US Food and Drug Administration approval may have felt like the finishing line, but a long and winding road to reimbursement still stretches ahead for Aduhelm (aducanumab).
With Medicare refusing to offer the novel Alzheimer’s med outside of the clinical trial setting, data from confirmatory studies could be critical to its future prospects.
Developers Biogen (Nasdaq: BIIB) and Eisai (TYO: 4523) have now released details of their plans for Phase IV research, designed to convert their US FDA Accelerated Approval into regular authorization.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze